Literature DB >> 26224760

Improving the Quality of Outpatient Diabetes Care Using an Information Management System: Results From the Observational VISION Study.

Joerg Weissmann1, Angelika Mueller1, Diethelm Messinger2, Christopher G Parkin3, Ildiko Amann-Zalan1.   

Abstract

BACKGROUND: This study aimed to evaluate the effects of information management system (IMS) use with individuals with type 1 and type 2 diabetes who were treated in outpatient settings.
METHODS: In this 7-month, prospective, observational study, 965 adults with diabetes, mean (SD) baseline HbA1c 8.61(1.2)% (70.6[13.1] mmol/mol), were recruited from 132 outpatient care centers in Germany and Denmark. HbA1c was measured at baseline, month 4, and month 7. IMS reports were generated from uploaded self-monitored blood glucose data and therapy adjustments were documented at months 1 and 4. Hypoglycemic events were documented.
RESULTS: Mean (SD) HbA1c decreased from baseline in type 1 and type 2 diabetes patients at month 4 (-0.61[1.03]% (-6.7[11.3] mmol/mol), n = 213; -0.88[1.22]% (-9.6[13.3] mmol/mol), n = 589, respectively) and month 7 (-0.64[1.02]% (-7.0[11.1] mmol/mol), n = 219; -0.93[1.27]% (-10.2[13.9] mmol/mol), n = 594, respectively), all P < .0001, with no increase in hypoglycemic events. Therapy was adjusted in 106(42.7)% type 1 and 349(52.4)% type 2 diabetes patients at months 1 and 105(42.3)% type 1 and 282(42.3)% type 2 diabetes patients at month 4. Physicians used IMS reports to make therapy adjustments in 90% of patients at month 1 and 86% of patients at month 4.
CONCLUSIONS: Integration of the IMS into outpatient care facilitates significant improvements in glycemic control.
© 2015 Diabetes Technology Society.

Entities:  

Keywords:  information management system; self-monitoring of blood glucose; type 1 diabetes; type 2 diabetes

Mesh:

Substances:

Year:  2015        PMID: 26224760      PMCID: PMC4738206          DOI: 10.1177/1932296815595984

Source DB:  PubMed          Journal:  J Diabetes Sci Technol        ISSN: 1932-2968


  31 in total

1.  International ethical guidelines for biomedical research involving human subjects.

Authors: 
Journal:  Bull Med Ethics       Date:  2002-10

2.  Benefits of self-monitoring blood glucose in the management of new-onset Type 2 diabetes mellitus: the St Carlos Study, a prospective randomized clinic-based interventional study with parallel groups.

Authors:  Alejandra Durán; Patricia Martín; Isabelle Runkle; Natalia Pérez; Rosario Abad; Mercedes Fernández; Laura Del Valle; Maria Fuencisla Sanz; Alfonso Luis Calle-Pascual
Journal:  J Diabetes       Date:  2010-09       Impact factor: 4.006

3.  The effect of glucose variability on the risk of microvascular complications in type 1 diabetes.

Authors:  Irl B Hirsch; Michael Brownlee
Journal:  Diabetes Care       Date:  2007-01       Impact factor: 19.112

4.  Post-prandial hyperglycemia is an important predictor of the incidence of diabetic microangiopathy in Japanese type 2 diabetic patients.

Authors:  Toshihiko Shiraiwa; Hideaki Kaneto; Takeshi Miyatsuka; Ken Kato; Kaoru Yamamoto; Ayaha Kawashima; Tsutomu Kanda; Masaaki Suzuki; Eiichi Imano; Munehide Matsuhisa; Masatsugu Hori; Yoshimitsu Yamasaki
Journal:  Biochem Biophys Res Commun       Date:  2005-10-14       Impact factor: 3.575

Review 5.  Should minimal blood glucose variability become the gold standard of glycemic control?

Authors:  Irl B Hirsch; Michael Brownlee
Journal:  J Diabetes Complications       Date:  2005 May-Jun       Impact factor: 2.852

Review 6.  Glycemic risk factors of diabetic vascular complications: the role of glycemic variability.

Authors:  Francesco Zaccardi; Dario Pitocco; Giovanni Ghirlanda
Journal:  Diabetes Metab Res Rev       Date:  2009-03       Impact factor: 4.876

7.  Assessment of diabetes-related distress.

Authors:  W H Polonsky; B J Anderson; P A Lohrer; G Welch; A M Jacobson; J E Aponte; C E Schwartz
Journal:  Diabetes Care       Date:  1995-06       Impact factor: 19.112

8.  2-Year follow-up to STeP trial shows sustainability of structured self-monitoring of blood glucose utilization: results from the STeP practice logistics and usability survey (STeP PLUS).

Authors:  Kevin Friedman; Jeannette Noyes; Christopher G Parkin
Journal:  Diabetes Technol Ther       Date:  2013-02-04       Impact factor: 6.118

9.  Self-monitoring of blood glucose in type 1 diabetes patients with insufficient metabolic control: focused self-monitoring of blood glucose intervention can lower glycated hemoglobin A1C.

Authors:  Svein Skeie; Gunn B B Kristensen; Siri Carlsen; Sverre Sandberg
Journal:  J Diabetes Sci Technol       Date:  2009-01

10.  Structured self-monitoring of blood glucose reduces glycated hemoglobin in insulin-treated diabetes.

Authors:  Noriko Kato; Jinyan Cui; Mitsutoshi Kato
Journal:  J Diabetes Investig       Date:  2013-04-18       Impact factor: 4.232

View more
  4 in total

1.  Patient generated health data use in clinical practice: A systematic review.

Authors:  George Demiris; Sarah J Iribarren; Katherine Sward; Solim Lee; Rumei Yang
Journal:  Nurs Outlook       Date:  2019-04-26       Impact factor: 3.250

2.  Opportunities and Challenges of Integrating Food Practice into Clinical Decision-Making.

Authors:  Mustafa Ozkaynak; Stephen Voida; Emily Dunn
Journal:  Appl Clin Inform       Date:  2022-02-23       Impact factor: 2.342

3.  Integrated Personalized Diabetes Management (PDM): Design of the ProValue Studies: Prospective, Cluster-Randomized, Controlled, Intervention Trials for Evaluation of the Effectiveness and Benefit of PDM in Patients With Insulin-Treated Type 2 Diabetes.

Authors:  Bernhard Kulzer; Wilfried Daenschel; Ingrid Daenschel; Erhard G Siegel; Wendelin Schramm; Christopher G Parkin; Diethelm Messinger; Joerg Weissmann; Zdenka Djuric; Angelika Mueller; Iris Vesper; Lutz Heinemann
Journal:  J Diabetes Sci Technol       Date:  2016-05-03

4.  PDM-ProValue meets cardiovascular outcome trials in diabetes.

Authors:  Katharina Fritzen; Oliver Schnell
Journal:  Cardiovasc Diabetol       Date:  2019-01-28       Impact factor: 9.951

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.